Drug Trial Radar · NCT03866187
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
236
Actual
Start
Mar 28, 2019
Primary completion
Oct 7, 2024
Study completion Oct 7, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.
Conditions
- Hepatitis B, Chronic
Interventions
ChAd155-hIi-HBV low dose formulationBiological
Participants in group A1 were scheduled to receive one dose of ChAd155-hIi-HBV low dose formulation on Day 1, by intramuscular injection in the deltoid of the non-dominant arm.
ChAd155-hIi-HBV high dose formulationBiological
Participants in groups B1 and B3 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the non-dominant arm. Participants in groups C1 and C2 were scheduled to receive one dose of ChAd155-hIi-HBV high dose formulation on Day 1 and Day 113 respectively, by intramuscular injection in the deltoid of the dominant arm.
HBc-HBs/AS01B-4 low dose formulationBiological
Participants in group A1 were scheduled to receive two doses of HBc-HBs/AS01B-4 low dose formulation, one on Day 113 and one on Day 169, and participants in group A2 were scheduled to receive four doses of the HBc-HBs/AS01B-4 low dose formulation, one dose each on Days 1, 57, 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
HBc-HBs/AS01B-4 high dose formulationBiological
Participants in group B1 were scheduled to receive two doses of HBc-HBs/AS01B-4 high dose formulation, one on Day 113 and one on Day 169; participants in group B2 were scheduled to receive four doses of HBc-HBs/AS01B-4 high dose formulation, one dose each on Days 1, 57, 113 and 169; participants in group C1 were scheduled to receive four co-administered doses of HBc-HBs/AS01B-4 high dose formulation on Days 1, 57, 113 and 169 and participants in group C2 were scheduled to receive two co-administered doses HBc-HBs/AS01B-4 high dose formulation on Days 113 and 169, by intramuscular injection in the deltoid of the non-dominant arm.
MVA-HBV low dose formulationBiological
Participants in group A1 were scheduled to receive one dose of MVA-HBV low dose formulation on Day 57, by intramuscular injection in the deltoid of the non-dominant arm.
MVA-HBV high dose formulationBiological
Participants in groups B1 and B3 were scheduled to receive one dose of MVA-HBV high dose formulation on Day 57 and Day 169 respectively, by intramuscular injection in the deltoid of the non-dominant arm. Participants in group C1 were scheduled to receive three co-administered doses of the MVA-HBV high dose formulation on Days 57, 113 and 169 and participants in group C2 were scheduled to receive one co-administered dose of the MVA-HBV high dose formulation on Day 169, by intramuscular injection in the deltoid of the dominant arm.
PlaceboDrug
Participants in group A3 were scheduled to receive four doses of placebo, one each on Days 1, 57, 113 and 169 and participants in group B3 were scheduled to receive two doses of placebo one each on Days 1 and 57, by intramuscular injection in the deltoid of the non-dominant arm. Participants in group C2 were scheduled to receive two co-administered doses of placebo on Day 1 and two co-administered doses of placebo on Day 57, by intramuscular injection in the deltoid of the dominant and non-dominant arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 1Time frame: Within 7 days after vaccination 1 occurring on Day 1
- Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 2Time frame: Within 7 days after vaccination 2 occurring on Day 57
- Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 3Time frame: Within 7 days after vaccination 3 occurring on Day 113
- Number of Participants Reporting Any Solicited Administration Site Events After Vaccination 4Time frame: Within 7 days after vaccination 4 occurring on Day 169
- Number of Participants Reporting Any Solicited Systemic Events After Vaccination 1Time frame: Within 7 days after vaccination 1 occurring on Day 1
- Number of Participants Reporting Any Solicited Systemic Events After Vaccination 2Time frame: Within 7 days after vaccination 2 occurring on Day 57
- Number of Participants Reporting Any Solicited Systemic Events After Vaccination 3Time frame: Within 7 days after vaccination 3 occurring on Day 113
- Number of Participants Reporting Any Solicited Systemic Events After Vaccination 4Time frame: Within 7 days after vaccination 4 occurring on Day 169
- Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After Vaccination 1Time frame: Within 30 days after vaccination 1 occurring on Day 1
- Number of Participants Reporting Any Unsolicited AEs After Vaccination 2Time frame: Within 30 days after vaccination 2 occurring on Day 57
- Number of Participants Reporting Any Unsolicited AEs After Vaccination 3Time frame: Within 30 days after vaccination 3 occurring on Day 113
- Number of Participants Reporting Any Unsolicited AEs After Vaccination 4Time frame: Within 30 days after vaccination 4 occurring on Day 169
- Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 1Time frame: Within 30 days after vaccination 1 occurring on Day 1
- Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 2Time frame: Within 30 days after vaccination 2 occurring on Day 57
- Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 3Time frame: Within 30 days after vaccination 3 occurring on Day 113
- Number of Participants With Hematological, Biochemical and Urinalysis Laboratory Abnormalities After Vaccination 4Time frame: Within 30 days after vaccination 4 occurring on Day 169
- Number of Participants Reporting Serious Adverse Events (SAEs)Time frame: From Day 1 until Day 337
- Number of Participants Reporting Potential Immune-mediated Diseases (pIMDs)Time frame: From Day 1 until Day 337
- Number of Participants Reporting Liver Disease-related (LDR) Adverse Events of Special Interest (AESIs)Time frame: From Day 1 until Day 337
- Number of Participants Reporting Hematological AESIsTime frame: From Day 1 until Day 337
- Number of Participants Reporting Medically-attended Adverse Events (MAEs)Time frame: From Day 1 until Day 337
Locations
43 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Antwerp, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Clichy, France
GSK Investigational Site
Créteil, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Strasbourg, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Bonn, Germany
GSK Investigational Site
Essen, Germany
GSK Investigational Site
Frankfurt, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Mainz, Germany
GSK Investigational Site
Pokfulam, Hong Kong
GSK Investigational Site
Krakow, Poland
GSK Investigational Site
Łańcut, Poland
GSK Investigational Site
Mysłowice, Poland
GSK Investigational Site
Poznan, Poland
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Córdoba, Spain
GSK Investigational Site
Granada, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Palma de Mallorca, Spain
GSK Investigational Site
Santander, Spain
GSK Investigational Site
Seville, Spain
GSK Investigational Site
TorrejOn Ardoz Madrid, Spain
GSK Investigational Site
Taichung, Taiwan
GSK Investigational Site
Taichung, Taiwan
GSK Investigational Site
Tainan, Taiwan
GSK Investigational Site
Taipei, Taiwan
GSK Investigational Site
Taoyuan, Taiwan
GSK Investigational Site
Bangkok, Thailand
GSK Investigational Site
Chiang Mai, Thailand
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.